Psychedelic Alpha’s Q3 2026 briefing scans drug development, policy, and research. Here’s what it is, what’s not stated, and how DMV cannabis pros can use it.

Federal lobbying hit record highs in Q2 2026 while the DEA targets tryptamines and Oregon reconsiders psilocybin program fees.

Psychedelic Alpha has introduced The Psychedelic News Feed Podcast, creating a new way to follow psychedelics developments. Here’s why DMV readers should care.

Definium Therapeutics reports another positive Phase 3 readout for DT120 in generalised anxiety disorder, with randomized data from the Panorama study now toplined.

What a new psilocybin trial update means for evidence standards in medical cannabis and patient care, plus why rigorous methods matter for DMV patients.

FDA officials outline a landmark regulatory framework for psychedelic drug development in the New England Journal of Medicine, focusing on depression and PTSD.

A power shift at Lykos Therapeutics could revive MDMA-assisted therapy—and Rick Doblin’s influence. Here’s what’s changing, why it matters, and how DMV residents should watch the next moves.

Definium Therapeutics reports Phase 3 topline success for LSD (DT120) in generalized anxiety disorder, following MDD progress. Here’s the clinical context and what DMV patients should watch.

FDA guidance, Phase 3 results and VA-led training signal psychedelic therapies edging closer to clinics. Here’s what practitioners—and DMV patients—should know now.

An interview with Husseini Manji, MD, shared by Psychedelic Alpha, points to plasticity-driven mechanisms, clinic-based models, REMS safety, and payer realities that psychedelic developers must solve next.

HRSA logged 59 comments on training and outpatient delivery models for potential FDA‑approved psychedelic therapies. We unpack what’s being explored, plus why credentials, clinics, and costs matter.

Johnson & Johnson leads an $85 million Series C round for Delix Therapeutics, signaling growing corporate interest in novel therapies.

Psychedelic Alpha reports that Risk Evaluation and Mitigation Strategies are likely to shape how FDA-approved psychedelic therapies are delivered. Here’s what to watch.

MDMA PTSD refiling, a first LSD Phase 3 readout, HRSA’s 59 RFI responses on psychedelic care access, J&J’s neuroplastogen bet, and an FDA pick to watch.